Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

• Status: Unknown status
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

• To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cooperative Study Group A for Hematology
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Gemcitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Patients who have refractory to first-line CHOP-like regimen

• Patients who have first relapse after

• first-line CHOP-like regimen

• upfront autologous or allogeneic hematopoietic stem cell transplantation

• Age 15 years or more

• ECOG performance status ≤ 2

• Adequate bone marrow function

• Adequate kidney,liver,cardiac

Exclusion Criteria:

• Patients who have received GEM or OX